Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

Publication Type:

Journal Article

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 26, Issue 28, p.4672-8 (2008)

Keywords:

2008, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Clinical Research Division, Female, Genotype, Haplotypes, Humans, Hypertension, paclitaxel, Polymorphism, Single Nucleotide, Proportional Hazards Models, Retrospective Studies, Statistics, Nonparametric, Survival Rate, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor-2

Abstract:

No biomarkers have been identified to predict outcome with the use of an antiangiogenesis agent for cancer. Vascular endothelial growth factor (VEGF) genetic variability has been associated with altered risk of breast cancer and variable promoter activity. Therefore, we evaluated the association of VEGF genotype with efficacy and toxicity in E2100, a phase III study comparing paclitaxel versus paclitaxel plus bevacizumab as initial chemotherapy for metastatic breast cancer.